Eidelman Virant Capital’s AbbVie ABBV Stock Holding History

Eidelman Virant Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$998K	Hold	7,325	–	–	0.73%	39
2022 Q2	$1.09M	Sell	7,325 -500	-6%	-$76.4K	0.79%	39
2022 Q1	$1.27M	Sell	7,825 -152	-2%	-$22.1K	0.68%	45
2021 Q4	$1.08M	Buy	7,977 +42	+0.5%	+$4.96K	0.39%	66
2021 Q3	$865K	Buy	7,935 +4,950	+166%	+$566K	0.33%	76
2021 Q2	$336K	Hold	2,985	–	–	0.13%	126
2021 Q1	$324K	Hold	2,985	–	–	0.13%	124
2020 Q4	$320K	Sell	2,985 -1,000	-25%	-$96.1K	0.14%	116
2020 Q3	$349K	Buy	+3,985	New	+$375K	0.19%	94
2013 Q3	–	Sell	-20,900	Closed	-$864K	–	154
2013 Q2	$864K	Buy	+20,900	New	+$914K	0.51%	58

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Eidelman Virant Capital's ABBV Position: Q3 2022 in Review

Eidelman Virant Capital held its AbbVie (ABBV) position steady in Q3 2022 at 7,325 shares worth $998K. The position accounts for 0.73% of the portfolio, ranked #39.

Eidelman Virant Capital first reported a position in ABBV in Q2 2013 and has held it in 10 quarters since. The position peaked at $1.27M in Q1 2022. 2,969 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.

Eidelman Virant Capital held 7,325 shares of AbbVie worth $998K as of Q3 2022.
Eidelman Virant Capital left its AbbVie share count unchanged in Q3 2022.
AbbVie made up 0.73% of Eidelman Virant Capital's portfolio in Q3 2022, its #39 holding.
Eidelman Virant Capital first reported a position in AbbVie in Q2 2013 and has held it in 10 quarters since.
Eidelman Virant Capital's AbbVie position peaked at $1.27M in Q1 2022.
2,969 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.

Based on Eidelman Virant Capital's 13F filing for Q3 2022, filed 25 Oct 2022.